Oncology Meeting Digest

Oligometastatic / Mets

1 study across 1 date

2026-05-17

OLIGOCARE — EORTC e2irradiate prospective SABR registry for oligometastases

OLIGOCARE (n~2500 pts, ~3500 mets): SABR local failure 5% at 1y and 11% at 3y; CRC carries higher progression risk; minimum PTV dose correlates with LC.

  • Local failure: 5% at 1 year, 11% at 3 years across all histologies.
  • Colorectal cancer subgroup: higher local/systemic progression risk vs other histologies — consistent with radiobiologic resistance and liver/lung metastatic propensity in CRC.
  • Minimum PTV dose (cold-spot dosimetry) correlates with local control — a dosimetric quality-assurance signal with direct planning optimization implications.
  • RCC SBRT (tweet 6): ~100% LC at 5 years reported via commentary link — sharply contrasts with CRC data and supports histology-stratified SABR eligibility frameworks.
  • Registry design without randomised comparator; performance-status selection bias and variable systemic therapy backgrounds limit efficacy inference; toxicity data not reported in source tweets.
  • At ~2500 patients, OLIGOCARE substantially exceeds prior randomised oligomets trials (SABR-COMET ~99 pts, ORIOLE ~54 pts) in sample size, though design differences preclude direct comparison.
📚 Sources (2)